Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
1
10%
Ph phase_1
9
90%

Phase Distribution

9

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
9(90.0%)
Phase 2Efficacy & side effects
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (90.0%)
Phase 21 (10.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

Study of SNX-5422 in TP53 Null Cancers

NCT02612285
completedphase_1

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

NCT02063958
completedphase_1

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

NCT01892046
completedphase_1

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

NCT00644072
completedphase_1

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

NCT01635712
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02612285Phase 2

Study of SNX-5422 in TP53 Null Cancers

Terminated
NCT02063958Phase 1

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Completed
NCT01892046Phase 1

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

Completed
NCT00644072Phase 1

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

Completed
NCT01635712Phase 1

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Completed
NCT01848756Phase 1

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

Terminated
NCT01851096Phase 1

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

Completed
NCT01611623Phase 1

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

Completed
NCT00506805Phase 1

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Completed
NCT00595686Phase 1

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10